“Oncosyne’s iCAN platform has been instrumental in advancing our clinical development of arfolitixorin. The organoid-based experiments not only confirmed the findings of the phase 3 AGENT trial but also provided novel insights into arfolitixorin’s mechanism of action, optimal drug combinations, and potential predictive biomarkers. Importantly, I believe these data played a key role in supporting discussions with regulatory authorities and ultimately […]
Investors 2
| Date | Name | Website |
| 10.07.2026 | Planet 9 C... | planet9ven... |
| 10.07.2026 | Farvatn Ve... | farvatnven... |